Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.The past nine months have been rough ones to be an Agenus (AGEN -0.43%) shareholder. The stock has collapsed by about 75% from the peak it set last June.Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target.Agenus shares could deliver an enormo ...